La Jolla Pharmaceutical Company CEO Acquires $199,500 in Stock (LJPC)

Share on StockTwits

La Jolla Pharmaceutical Company (NASDAQ:LJPC) CEO George F. Tidmarsh purchased 19,000 shares of the stock on the open market in a transaction that occurred on Wednesday, July 23rd. The stock was purchased at an average cost of $10.50 per share, for a total transaction of $199,500.00. Following the purchase, the chief executive officer now directly owns 1,410,086 shares of the company’s stock, valued at approximately $14,805,903. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) opened at 11.26 on Friday. La Jolla Pharmaceutical Company has a 52 week low of $0.16 and a 52 week high of $19.50. The stock’s 50-day moving average is $9.5 and its 200-day moving average is $9.32. The company’s market cap is $88.6 million.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) last posted its quarterly earnings results on Friday, May 2nd. The company reported ($0.93) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.91) by $0.02. On average, analysts predict that La Jolla Pharmaceutical Company will post $-3.25 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on LJPC shares. Analysts at Wedbush reiterated a “buy” rating on shares of La Jolla Pharmaceutical Company in a research note on Tuesday, July 15th. Separately, analysts at Noble Financial raised their price target on shares of La Jolla Pharmaceutical Company from $34.00 to $38.00 in a research note on Wednesday, July 9th. They now have a “buy” rating on the stock. Finally, analysts at Zacks downgraded shares of La Jolla Pharmaceutical Company to a “neutral” rating in a research note on Wednesday, May 7th. They now have a $9.70 price target on the stock. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. La Jolla Pharmaceutical Company has an average rating of “Buy” and an average price target of $27.14.

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the development of therapeutic agents that inhibit the activity of galectins as a means of treating human diseases such as chronic organ failure and cancer.

Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.

Latest News

Law Enforcement: Man Ingested Girlfriend’s Organs
Law Enforcement: Man Ingested Girlfriend’s Organs
Apple Confirms iPhone 6 Record Pre-Orders
Apple Confirms iPhone 6 Record Pre-Orders
Ruble Falls to Record Low Following Sanctions Over Ukraine
Ruble Falls to Record Low Following Sanctions Over Ukraine
Male Birth Control Possibly Available by 2017
Male Birth Control Possibly Available by 2017
NFL Retirees: Three in Ten Face Cognitive Problems
NFL Retirees: Three in Ten Face Cognitive Problems
Apple Pay Snubbed by Wal-Mart
Apple Pay Snubbed by Wal-Mart


One Response

  1. Lou Caserin says:

    George has been buying stock with his own funds,steadily all year.
    Very very positive. I will keep adding to my position with him.
    Undervalued stock,,by a ton

Leave a Reply

 
© 2006-2014 WKRB News.